Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enhanced autologous PSMA-CAR T
- Development stage
- Phase 1
- Lead developer
- Shanghai ChangZheng Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Enhanced autologous PSMA-CAR T is a Chimeric Antigen Receptor (CAR) T cell therapy that utilizes a patient's own (autologous) T cells, which are genetically engineered to express a CAR targeting Prostate-Specific Membrane Antigen (PSMA). This therapy is being developed by Shanghai Changzheng Hospital for the treatment of refractory castration-resistant prostate cancer.
- Other names
- Enhanced autologous PSMA chimeric antigen receptor T cellsCART-PSMA cellsEnhanced autologous PSMA-CAR T-Shanghai Changzheng Hospital
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on enhanced autologous PSMA-CAR T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enhanced autologous PSMA-CAR T.